Welcome to Skilled in the Art. I’m Law.com IP reporter Scott Graham. Today is going to be life sciences day at SitA. I’ve got a few quick hits involving CRISPR gene editing patents, a battle between cancer treatment biopharmas, and the latest patent eligibility dispute in the medical diagnostics space. As always you can email me your own thoughts and follow me on Twitter.

Photo: Wikimedia Commons

CRISPR Battle Is Back on at the PTAB

Summer’s here, which means it’s sequel season. “Toy Story 4.” “Godzilla: King of the Monsters.” “CRISPR Interference II: Return to the PTAB.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]